Minerva Neurosciences, Inc. (NERV)
- Previous Close
1.6100 - Open
1.6800 - Bid 1.1500 x 200
- Ask 2.1500 x 200
- Day's Range
1.5900 - 1.7400 - 52 Week Range
1.1500 - 3.6900 - Volume
3,858 - Avg. Volume
18,938 - Market Cap (intraday)
11.407M - Beta (5Y Monthly) -0.51
- PE Ratio (TTM)
8.58 - EPS (TTM)
0.1900 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
www.minervaneurosciences.comRecent News: NERV
View More
Performance Overview: NERV
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NERV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NERV
View MoreValuation Measures
Market Cap
11.41M
Enterprise Value
-9.96M
Trailing P/E
8.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.04%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
1.44M
Diluted EPS (ttm)
0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
21.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.48M